Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax TSLA Option Income Strategy ETF (TSLY) vs Viatris Inc (VTRS) Price & Performance

YieldMax TSLA Option Income Strategy ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

YieldMax TSLA Option Income Strategy ETF vs Viatris Inc — how do they compare? YieldMax TSLA Option Income Strategy ETF trades at $21.57, while Viatris Inc trades at $16.26 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Viatris Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

TSLYVTRS
Sector
Income / Options OverlayHealth
52-Week High
$48.25$17.86
52-Week Low
$20.49$9.49
Market Cap
$18.69B
Enterprise Value
$30.80B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax TSLA Option Income Strategy ETF

TSLY trades at $21.51, down 1.01% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF generates high income through weekly distributions, but faces capped upside due to its covered call strategy on Tesla. Recent news highlights concerns over missed Tesla rallies and reduced upside capture, while distributions remain consistent, averaging around $0.28 per share recently.

Outlook is cautious due to structural limitations in capturing Tesla's gains, presenting income opportunity but significant growth risk. Investors face volatility from Tesla's performance and potential return of capital in distributions, warranting careful assessment of income versus capital appreciation goals.

Viatris Inc

Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.

Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.

Returns comparison

Trailing returns across standard periods

About YieldMax TSLA Option Income Strategy ETF

TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.

Read more on TSLY

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS